<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940823</url>
  </required_header>
  <id_info>
    <org_study_id>CVEC-AVB</org_study_id>
    <secondary_id>GRSC-2005</secondary_id>
    <nct_id>NCT00940823</nct_id>
  </id_info>
  <brief_title>The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma</brief_title>
  <official_title>The Ahmed Versus Baerveldt (AVB) Study: Prospective, Multicenter Trial Comparing the Ahmed-FP7 Valve With the Baerveldt-350 Implant in Treating Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Credit Valley EyeCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaucoma Research Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Credit Valley EyeCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of the Ahmed valve and the
      Baerveldt implant in treating refractory glaucoma. Eligible patients will be recruited from
      multiple study centers and randomized to a glaucoma drainage device for implantation. They
      will be followed long-term based upon outcome measures including intraocular pressure,
      glaucoma medication use, visual acuity, complications of the surgery and further treatments
      required.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      The use of a glaucoma drainage device (GDD) is indicated in cases of refractory glaucoma not
      responsive to conventional medication, laser and surgical therapy. Most of these patients are
      at high risk for surgical failure, with serious concomitant ocular and systemic diseases.
      GDD's are increasingly being used to obtain low target intraocular pressures (IOP) in
      patients who have failed antimetabolite trabeculectomy or have active neovascular glaucoma.

      Since Molteno's original design, several drainage devices have become commercially available
      for implantation. Currently, the two most commonly used devices are the Ahmed Glaucoma Valve
      (AGV) (New World Medical, Inc., Rancho Cucamonga, CA), and the Baerveldt Glaucoma Device
      (BGD) (Advanced Medical Optics, Santa Ana, CA). The AGV, with a venture-based
      flow-restrictive valve is helpful in minimizing postoperative hypotony and complications
      associated with hypotony, including flat anterior chamber, choroidal effusions, and
      suprachoroidal hemorrhage. However, there appears to be a high rate of encapsulation and
      hypertension associated with this device, and increased requirement of postoperative glaucoma
      medication use. The BGD, a non-valved device, requires early ligature of flow by the use of a
      suture restriction to allow adequate time for bleb formation. Although this can result in an
      initial post-operative hypertension phase, it results in less encapsulation and theoretically
      fewer postoperative glaucoma medications and better IOP control. However, the lack of a
      flow-restrictor and the large filtering surface area may result in a greater risk for
      hypotony related complications.

      Although several studies comparing the AGV and BGD have been reported, they have all been
      retrospective, nonrandomized, small scale, and compare different patient populations. The
      results have been inconclusive and conflicting in evaluating the relative efficacy and
      characteristics of these two devices, and further research needs to be done in order to
      answer these questions.

      Objective:

      The Ahmed vs. Baerveldt (AVB) Study is the first multicenter prospective randomized clinical
      trial comparing the Ahmed FP7 valve and the Baerveldt-350 tube shunt glaucoma drainage
      devices. Primary outcome is surgical failure, a composite criteria evaluating the intraocular
      pressure lowering effect of the devices, complications of the surgery, treatments for
      complications, glaucoma medication use, and the preservation of visual acuity. Secondary
      outcomes will evaluate these variables individually, and any non-glaucoma related ocular
      pathology and required interventions.

      AVB Study Manual:

      An AVB Study Manual including the study design and protocol, standardized surgical technique,
      patient education and consent form, and data collection protocol was distributed to each
      clinical site. The contents of the manual received ethics approval by the Institutional
      Review Board (IRB) at the primary site.

      Study Organization:

        1. Investigator Committee (IC): Composed of study investigators and under the leadership of
           the Study Chair. The IC's responsibilities are defined below:

             1. Designing the study protocol to ensure valid scientific method and proper ethical
                conduct.

             2. Overseeing clinical centers to ensure that the protocol and ethical standards of
                the study are being upheld.

             3. Overseeing the Data Acquisition &amp; Statistical Center to ensure that all practices
                are in accordance with those outlined in the protocol, and meet the ethical
                standards of the study.

             4. Drafting and editing study documents critically for intellectual content and
                ethical considerations.

        2. Clinical Centers (CC): Composed of study sites led by a Site Primary Investigator, whose
           responsibilities are defined below:

             1. Enrolling patients in the study after determining eligibility and providing patient
                education. Informed consent must be written.

             2. Ensuring that the study protocol and ethical standards of the study are upheld.

             3. Ensuring that the study adheres to the policies set forth by the local
                Institutional/Ethical Review Board.

             4. Acquiring study data and making it available to the Data Monitoring &amp; Statistics
                Committee.

        3. Data Acquisition &amp; Statistical Center (DASC): Composed of Study Director and Study
           Statistician, with the following responsibilities:

             1. Acquiring study data from each Clinical Center using the online study database
                (http://www.avsbstudy.com)

             2. Statistical analysis of the study data.

      Methods:

      Patient Enrollment and Treatment Assignment:

      Patients were recruited from 7 study sites by 10 surgeons. After patient eligibility and
      written informed consent was obtained by the Site PI, randomization to placement of an Ahmed
      FP7 valve or a Baerveldt-350 tube shunt was made by coin toss.

      Pre-operative data collection:

      The following data was collected in the 3 months prior to surgery: date of birth, gender,
      race, glaucoma diagnosis and etiology, past ocular history (diagnoses, surgical and laser
      procedures), best corrected visual acuity, intraocular pressure, glaucoma medication use,
      abnormal slit lamp findings, and abnormal fundus exam findings.

      Surgical Procedure:

      The surgical procedures used for the AVB Study are standardized, and any complications during
      surgery will be noted and defined.

      Ahmed FP7 valve implantation:

      A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation
      as required. A 90-degree conjunctival peritomy was followed by blunt dissection to mobilize a
      fornix or limbus-based conjunctival flap over the area of intended device implantation.
      Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under
      the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain
      hemostasis.

      The Ahmed Glaucoma Valve model FP-7 was primed with balanced salt solution, and placed in the
      intended quadrant. The plate was sutured to sclera 8-10mm posterior to the limbus with two
      8-0 or 10-0 Nylon sutures.

      A paracentesis was made if required, and a viscoelastic agent used to form the anterior
      chamber. A 22-gauge needle was used to create needle tract into the anterior chamber.

      The tube was trimmed, and placed into the anterior chamber through the needle tract. The tube
      was attached to the sclera using a 10-0 Nylon suture if required. A sclera or corneal graft
      was placed over the tube and sutured to the sclera with 10-0 Nylon.

      The conjunctival flap was closed with 8-0 or 10-0 Vicryl suture. At the conclusion of the
      case, Maxitrol ointment was placed on the eye. No patients were patched, although shields
      were given to patients. That day, patients were started on antibiotic and steroid eye drops.
      A cycloplegic was used as indicated.

      Baerveldt-350 tube shunt implantation:

      A superior or inferior corneal traction suture with 8-0 Vicryl was placed for globe fixation.
      A 90 to 120-degree conjunctival peritomy was followed by blunt dissection to mobilize a
      fornix or limbus-based conjunctival flap over the area of intended device implantation.
      Non-preserved lidocaine 1% was injected under the conjunctival flap, posteriorly, and under
      the extraocular muscle bellies with a blunt cannula. Gentle cautery was used to obtain
      hemostasis.

      Both adjacent extraocular muscles were isolated using a muscle hook. 4-0 silk sutures were
      used for fixation if necessary.

      The Baerveldt drainage device model BG101-350 was checked with balanced salt solution, and a
      4-0 Nylon releasable intraluminal suture was placed. A 7-0 or 8-0 Vicryl ligature suture was
      placed around the tube. The plate was placed in the intended quadrant and under the muscle
      bellies. The plate was sutured to the sclera 8-12mm posterior to the limbus with two 8-0 or
      10-0 Nylon sutures.

      A paracentesis was made if it was required, and a viscoelastic agent used to form the
      anterior chamber. A 22-gauge needle was used to create needle tract into the anterior
      chamber. The tube was trimmed, and placed into the anterior chamber through the needle tract.
      The tube was attached to the sclera using a 10-0 Nylon suture if required. A sclera or
      corneal graft was placed over the tube and sutured to the sclera.

      The conjunctival flap was closed with an 8-0 or 10-0 Vicryl suture. At the conclusion of the
      case, Atropine 1% drops and Maxitrol ointment was placed on the eye. No patients were
      patched, although shields were given to patients. On the day of surgery, patients were
      started on antibiotics and steroid eye drops. A cycloplegic agent was used as indicated.

      Post-operative data collection:

      Patients were seen post-operatively at a minimum of 1 day, 1 week, 2 weeks, 1 month, 2
      months, 3 months, 6 months, 12 months, 18 months 2 years, 3 years, 4 years and 5 years.
      Further visits were made as deemed necessary. At each visit, the following data was
      collected:

        1. Intraocular pressure (IOP) by Goldmann Applanation Tonometry

        2. Visual Acuity (VA) using a Snellen Chart or Low Vision Chart

        3. Glaucoma Medication Use

        4. Slit Lamp Biomicroscopy &amp; Ophthalmoscopy

        5. Complications of Surgery

        6. Interventions/Treatment of Complications

      Outcome measures:

      Based upon the pre-operative data and post-operative results, a study outcome will be
      assigned to each patient, as defined below:

      Complete Success: (requires all of the following criteria)

        1. IOP: 5 mmHg &lt;= IOP &lt;= 18 mmHg with a reduction in IOP of 20% or greater from baseline at
           every visit after 3 months.

        2. Medications: No anti-glaucoma medications are required.

        3. Complications: No vision threatening complications related to the implant/surgery.

        4. Interventions: No additional glaucoma surgery or laser procedures are allowed.

        5. Vision: No greater than a doubling of the mean angle of resolution (logMAR), which
           corresponds to approximately 2 Snellen lines.

      Qualified Success: (requires all of the following criteria)

        1. IOP: 5 mmHg &lt;= IOP &lt;= 18 mmHg with a reduction in IOP of 20% or greater from baseline,
           with no two consecutive visits after 3 months which do not meet this criterion.

        2. Medications: Anti-glaucoma medications may be used.

        3. Surgery/Complications: No vision threatening complications or surgery occurred after
           implantation of the GDD.

        4. Interventions: Surgical and laser interventions to correct non-vision threatening
           complications of implant/surgery are allowed, but no additional glaucoma procedures are
           allowed.

        5. Vision: No progression to no light perception.

      Failure: (if any of the following criteria are met)

        1. IOP: IOP &lt;5 mmHg or &gt;18 mmHg or reduction &lt;20% from pre-operative IOP in two consecutive
           visits after 3 months.

        2. Surgery/Complications: Vision threatening complications or surgery required that is
           related to the implant. This includes severe choroidal effusions requiring drainage,
           suprachoroidal hemorrhage, endophthalmitis or malignant glaucoma requiring surgery.

        3. Interventions: An additional glaucoma procedure is required (e.g. cyclodestruction, gold
           shunt implantation).

        4. Vision: Progression to no light perception.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Surgical Failure (Composite Measure)</measure>
    <time_frame>5 years</time_frame>
    <description>IOP out of target range (5-18 mmHg inclusive) or &lt;20% reduction from baseline for 2 consecutive visits after 3 months.
De novo glaucoma surgery required (e.g., cyclodestructive procedure, additional tube shunt).
Removal of the implant.
Severe vision loss related to the surgery (endophthalmitis, suprachoroidal hemorrhage with vision loss, enucleation, evisceration, or phthisis bulbi) or progression to no light perception for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-glaucoma Medications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LogMAR Snellen Visual Acuity</measure>
    <time_frame>5 years</time_frame>
    <description>Visual acuity (VA) was tested monocularly (one eye at a time) using the manifest refraction adjusted for optical infinity using a standard Snellen Visual Acuity chart at 20 feet. Normal vision, or 20/20 vision, means that the participant can see at 20 feet what a healthy control can also see at 20 feet. Legal blindness, or 20/200 vision, means the participant can see at 20 feet what a healthy control can see at 200 feet. Hence, an increasing denominator implies visual impairment. Counting fingers was designated as 20/2000 vision, hand motions was 20/16000, light perception was 20/32000 and no light perception was 20/64000. To allow for appropriate statistical analysis, logMAR Snellen Visual Acuity was calculated using the formula: -logMAR (Snellen Acuity). This means that normal vision (20/20) would correspond to a value of 0, legal blindness (20/200) would correspond to a value of 1, and no light perception (20/64000) would correspond to 3.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complications During or After Surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Interventions After Surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Ahmed FP7 Valve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baerveldt-350 Tube</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed FP7 Valve</intervention_name>
    <description>Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.</description>
    <arm_group_label>Ahmed FP7 Valve</arm_group_label>
    <other_name>New World Medical</other_name>
    <other_name>AGV FP7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt-350 Tube</intervention_name>
    <description>Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.</description>
    <arm_group_label>Baerveldt-350 Tube</arm_group_label>
    <other_name>Advanced Medical Optics</other_name>
    <other_name>BG 101-350</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18.

          -  Inadequately controlled glaucoma determined as intraocular pressure (IOP) greater than
             target, which has not responded to conventional medical and surgical therapy.

          -  Patients with significant conjunctival scarring or high-risk disease (active
             neovascular glaucoma) precluding antimetabolite trabeculectomy will be included in the
             study.

          -  Provide written informed consent to participate in the study.

        Exclusion Criteria:

          -  Age less than 18.

          -  Patient will undergo an additional procedure at the time of glaucoma drainage device
             implantation (i.e. lensectomy, penetrating keratoplasty)

          -  No light perception vision.

          -  Patient has already been enrolled in the study in the contralateral eye.

          -  Patient is unwilling or unable to provide informed consent to participate in the
             study, or adhere to the study requirements including implant randomization and
             required follow-up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iqbal K Ahmed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Toronto Department of Ophthalmology &amp; Vision Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Panos G Christakis, BS</last_name>
    <role>Study Director</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James C Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Ophthalmology &amp; Visual Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey W Kalenak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drs. Massaro &amp; Kalenak, SC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis B Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey A Kammer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology and Visual Sciences: Vanderbilt University, School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul J Harasymowycz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Montreal: Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan J Mura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of Las Condes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eugene and Marilyn Glick Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs. Massaro and Kalenak</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit ValleyEC</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L5L 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Glaucoma Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Las Condes</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Syed HM, Law SK, Nam SH, Li G, Caprioli J, Coleman A. Baerveldt-350 implant versus Ahmed valve for refractory glaucoma: a case-controlled comparison. J Glaucoma. 2004 Feb;13(1):38-45.</citation>
    <PMID>14704542</PMID>
  </reference>
  <reference>
    <citation>Wang JC, See JL, Chew PT. Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population. Ophthalmology. 2004 Jul;111(7):1383-8.</citation>
    <PMID>15234141</PMID>
  </reference>
  <reference>
    <citation>Tsai JC, Johnson CC, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome. Ophthalmology. 2003 Sep;110(9):1814-21.</citation>
    <PMID>13129882</PMID>
  </reference>
  <reference>
    <citation>Tsai JC, Johnson CC, Kammer JA, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon. Ophthalmology. 2006 Jun;113(6):913-7.</citation>
    <PMID>16751034</PMID>
  </reference>
  <reference>
    <citation>Goulet RJ 3rd, Phan AD, Cantor LB, WuDunn D. Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant. Ophthalmology. 2008 Jul;115(7):1141-7. doi: 10.1016/j.ophtha.2007.10.034. Epub 2007 Dec 27.</citation>
    <PMID>18164068</PMID>
  </reference>
  <reference>
    <citation>Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, Bacharach J, Panek WC. Initial clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1995 Jul;120(1):23-31. Erratum in: Am J Ophthalmol. 1995 Nov;120(5):684.</citation>
    <PMID>7611326</PMID>
  </reference>
  <reference>
    <citation>Huang MC, Netland PA, Coleman AL, Siegner SW, Moster MR, Hill RA. Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant. Am J Ophthalmol. 1999 Jan;127(1):27-33.</citation>
    <PMID>9932995</PMID>
  </reference>
  <reference>
    <citation>Krishna R, Godfrey DG, Budenz DL, Escalona-Camaa√±o E, Gedde SJ, Greenfield DS, Feuer W, Scott IU. Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants. Ophthalmology. 2001 Mar;108(3):621-6.</citation>
    <PMID>11237919</PMID>
  </reference>
  <reference>
    <citation>Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, LaBree L, Heuer DK. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994 Aug;101(8):1456-63; discussion 1463-4.</citation>
    <PMID>8058290</PMID>
  </reference>
  <reference>
    <citation>Britt MT, LaBree LD, Lloyd MA, Minckler DS, Heuer DK, Baerveldt G, Varma R. Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: is bigger better? Ophthalmology. 1999 Dec;106(12):2312-8.</citation>
    <PMID>10599663</PMID>
  </reference>
  <reference>
    <citation>Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed Glaucoma Valve. Am J Ophthalmol. 2003 Dec;136(6):1001-8.</citation>
    <PMID>14644209</PMID>
  </reference>
  <reference>
    <citation>Law SK, Nguyen A, Coleman AL, Caprioli J. Comparison of safety and efficacy between silicone and polypropylene Ahmed glaucoma valves in refractory glaucoma. Ophthalmology. 2005 Sep;112(9):1514-20.</citation>
    <PMID>16005977</PMID>
  </reference>
  <reference>
    <citation>Ayyala RS, Harman LE, Michelini-Norris B, Ondrovic LE, Haller E, Margo CE, Stevens SX. Comparison of different biomaterials for glaucoma drainage devices. Arch Ophthalmol. 1999 Feb;117(2):233-6.</citation>
    <PMID>10037569</PMID>
  </reference>
  <reference>
    <citation>Ayyala RS, Michelini-Norris B, Flores A, Haller E, Margo CE. Comparison of different biomaterials for glaucoma drainage devices: part 2. Arch Ophthalmol. 2000 Aug;118(8):1081-4.</citation>
    <PMID>10922202</PMID>
  </reference>
  <reference>
    <citation>Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD; Tube Versus Trabeculectomy Study Group. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005 Aug;140(2):275-87.</citation>
    <PMID>16086949</PMID>
  </reference>
  <reference>
    <citation>Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol. 2007 Jan;143(1):23-31. Epub 2006 Sep 1.</citation>
    <PMID>17054896</PMID>
  </reference>
  <reference>
    <citation>Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol. 2007 Jan;143(1):9-22. Epub 2006 Sep 1.</citation>
    <PMID>17083910</PMID>
  </reference>
  <results_reference>
    <citation>Christakis PG, Tsai JC, Zurakowski D, Kalenak JW, Cantor LB, Ahmed II. The Ahmed Versus Baerveldt study: design, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011 Nov;118(11):2172-9. doi: 10.1016/j.ophtha.2011.05.003. Epub 2011 Sep 9.</citation>
    <PMID>21906813</PMID>
  </results_reference>
  <results_reference>
    <citation>Christakis PG, Kalenak JW, Zurakowski D, Tsai JC, Kammer JA, Harasymowycz PJ, Ahmed II. The Ahmed Versus Baerveldt study: one-year treatment outcomes. Ophthalmology. 2011 Nov;118(11):2180-9. doi: 10.1016/j.ophtha.2011.05.004. Epub 2011 Sep 1.</citation>
    <PMID>21889801</PMID>
  </results_reference>
  <results_reference>
    <citation>Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013 Nov;120(11):2232-40. doi: 10.1016/j.ophtha.2013.04.018. Epub 2013 Jun 21.</citation>
    <PMID>23796764</PMID>
  </results_reference>
  <results_reference>
    <citation>Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, Mura JJ, Cantor LB, Ahmed II. The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes. Ophthalmology. 2016 Oct;123(10):2093-102. doi: 10.1016/j.ophtha.2016.06.035. Epub 2016 Aug 17.</citation>
    <PMID>27544023</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <results_first_submitted>August 21, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Credit Valley EyeCare</investigator_affiliation>
    <investigator_full_name>Panos G. Christakis</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <keyword>Glaucoma Drainage Device</keyword>
  <keyword>Aqueous Shunt Implant</keyword>
  <keyword>Ahmed Valve</keyword>
  <keyword>Baerveldt Tube</keyword>
  <keyword>Refractory Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ahmed Group</title>
          <description>Ahmed FP7 Valve Implant</description>
        </group>
        <group group_id="P2">
          <title>Baerveldt Group</title>
          <description>Baerveldt-350 Implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ahmed Group</title>
          <description>Patients received an Ahmed-FP7 valve implant at the time of surgery.</description>
        </group>
        <group group_id="B2">
          <title>Baerveldt Group</title>
          <description>Patients received a Baerveldt-350 implant at the time of surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="17"/>
                    <measurement group_id="B2" value="67" spread="15"/>
                    <measurement group_id="B3" value="66" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="10.5"/>
                    <measurement group_id="B2" value="31.7" spread="11.1"/>
                    <measurement group_id="B3" value="31.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glaucoma Medication Use</title>
          <units>medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.0"/>
                    <measurement group_id="B2" value="3.1" spread="1.1"/>
                    <measurement group_id="B3" value="3.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Laser Therapies</title>
          <units>laser procedures</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="1.1"/>
                    <measurement group_id="B2" value="1.0" spread="1.1"/>
                    <measurement group_id="B3" value="0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Ocular Surgeries</title>
          <units>Ocular Surgeries</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="1.3"/>
                    <measurement group_id="B2" value="1.6" spread="1.1"/>
                    <measurement group_id="B3" value="1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean logMAR (converted) Visual Acuity</title>
          <description>LogMAR Visual Acuity is calculated by taking the log(Snellen Acuity/20). Normal vision (20/20) corresponds to 0 and complete blindness (no light perception, designated as 20/64000) corresponds to 3.5.
Hence, the lower the logMAR value, the better the vision.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="1.0"/>
                    <measurement group_id="B2" value="1.3" spread="1.1"/>
                    <measurement group_id="B3" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Surgical Failure (Composite Measure)</title>
        <description>IOP out of target range (5-18 mmHg inclusive) or &lt;20% reduction from baseline for 2 consecutive visits after 3 months.
De novo glaucoma surgery required (e.g., cyclodestructive procedure, additional tube shunt).
Removal of the implant.
Severe vision loss related to the surgery (endophthalmitis, suprachoroidal hemorrhage with vision loss, enucleation, evisceration, or phthisis bulbi) or progression to no light perception for any reason.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>Ahmed FP7 Valve Implant</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>Baerveldt-350 Implant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Failure (Composite Measure)</title>
          <description>IOP out of target range (5-18 mmHg inclusive) or &lt;20% reduction from baseline for 2 consecutive visits after 3 months.
De novo glaucoma surgery required (e.g., cyclodestructive procedure, additional tube shunt).
Removal of the implant.
Severe vision loss related to the surgery (endophthalmitis, suprachoroidal hemorrhage with vision loss, enucleation, evisceration, or phthisis bulbi) or progression to no light perception for any reason.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP)</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>124 patients were randomized to the Ahmed Group.</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>114 patients were randomized to the Ahmed Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="5.9"/>
                    <measurement group_id="O2" value="13.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-glaucoma Medications</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>124 patients were randomized to the Ahmed Group.</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>114 patients were randomized to the Ahmed Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-glaucoma Medications</title>
          <units>glaucoma medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.5"/>
                    <measurement group_id="O2" value="1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LogMAR Snellen Visual Acuity</title>
        <description>Visual acuity (VA) was tested monocularly (one eye at a time) using the manifest refraction adjusted for optical infinity using a standard Snellen Visual Acuity chart at 20 feet. Normal vision, or 20/20 vision, means that the participant can see at 20 feet what a healthy control can also see at 20 feet. Legal blindness, or 20/200 vision, means the participant can see at 20 feet what a healthy control can see at 200 feet. Hence, an increasing denominator implies visual impairment. Counting fingers was designated as 20/2000 vision, hand motions was 20/16000, light perception was 20/32000 and no light perception was 20/64000. To allow for appropriate statistical analysis, logMAR Snellen Visual Acuity was calculated using the formula: -logMAR (Snellen Acuity). This means that normal vision (20/20) would correspond to a value of 0, legal blindness (20/200) would correspond to a value of 1, and no light perception (20/64000) would correspond to 3.5.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>124 patients were randomized to the Ahmed Group.</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>114 patients were randomized to the Ahmed Group.</description>
          </group>
        </group_list>
        <measure>
          <title>LogMAR Snellen Visual Acuity</title>
          <description>Visual acuity (VA) was tested monocularly (one eye at a time) using the manifest refraction adjusted for optical infinity using a standard Snellen Visual Acuity chart at 20 feet. Normal vision, or 20/20 vision, means that the participant can see at 20 feet what a healthy control can also see at 20 feet. Legal blindness, or 20/200 vision, means the participant can see at 20 feet what a healthy control can see at 200 feet. Hence, an increasing denominator implies visual impairment. Counting fingers was designated as 20/2000 vision, hand motions was 20/16000, light perception was 20/32000 and no light perception was 20/64000. To allow for appropriate statistical analysis, logMAR Snellen Visual Acuity was calculated using the formula: -logMAR (Snellen Acuity). This means that normal vision (20/20) would correspond to a value of 0, legal blindness (20/200) would correspond to a value of 1, and no light perception (20/64000) would correspond to 3.5.</description>
          <units>logMAR units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complications During or After Surgery</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>124 patients were randomized to the Ahmed Group.</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>114 patients were randomized to the Ahmed Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complications During or After Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Interventions After Surgery</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ahmed Group</title>
            <description>124 patients were randomized to the Ahmed Group.</description>
          </group>
          <group group_id="O2">
            <title>Baerveldt Group</title>
            <description>114 patients were randomized to the Ahmed Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Interventions After Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ahmed Group</title>
          <description>Ahmed FP7 Valve Implant</description>
        </group>
        <group group_id="E2">
          <title>Baerveldt Group</title>
          <description>Baerveldt-350 Implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Suprachoroidal Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Phthisis Bulbi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Progression to no light perception</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Device Explantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Evisceration or enucleation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypotony Requiring Additional Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aqueous misdirection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Shallow Anterior Chamber</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="124"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Choroidal Effusions</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tube Complications</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="124"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Corneal Edema</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cataract Progression</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Encapsulated Bleb</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Motility Disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>High IOP requiring surgery</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="124"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Using predetermined IOP cutoffs may not reflect individual patient outcomes.
Visual field progression was not an outcome criteria due to the poor baseline vision of patients.
Results can only be applied to patients with advanced glaucoma.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Iqbal Ike K. Ahmed</name_or_title>
      <organization>Prism Eye Institute</organization>
      <phone>905-456-3937</phone>
      <email>ike.ahmed@utoronto.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

